At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 131 enrolled
Drug / intervention
Entecavirdrug
Likely dose
Entecavir 0.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study to Describe the Antiviral Effect of Entecavir (ETV) in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection Who Are Nucleoside-Naive
In Brief
A Phase 4 clinical trial evaluating Entecavir for Hepatitis B Infection. Completed, enrolled 131 participants across 27 sites in 5 countries.
Detailed Summary
The purpose of this clinical research study is to develop observational clinical experience with the use of entecavir in participants who are either of Black/African-American race or of Hispanic ethnicity.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis B Infection
CountriesBrazil, Mexico, Puerto Rico, South Africa, United States
Collaborators--
Timeline
Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 2006
Enrollment StartNov 2006
Primary CompletionMar 2011
TodayJul 2026
First PostedSep 1, 2006
Enrollment StartNov 1, 2006
Primary CompletionMar 1, 2011
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 19.8 years ago
Interventions
Entecavirdrug
Tablets, Oral, 0.5 mg, once daily, up to 52 weeks